Myeloid Growth Factors

Crawford, Jeffrey; Armitage, Jamés O.; Balducci, Lodovico; Becker, Pamela S.; Blayney, Douglas W.; Cataland, Spero R.; Heaney, Mark L.; Hudock, Susan; Kloth, Dwight D.; Kuter, David J.; Lyman, Gary H.; McMahon, Brandon; Rugo, Hope S.; Saad, Ayman; Schwartzberg, Lee S.; Shayani, Sepideh; Steensma, David P.; Talbott, Mahsa; Vadhan‐Raj, Saroj; Westervelt, Peter; Westmoreland, Michael; Dwyer, Mary A.; Ho, Maria Yi

doi:10.6004/jnccn.2009.0006

Cited by 98 publications

(19 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), whereas primary prophylaxis should not be performed in patients with a low risk of febrile neutropenia (< 10%). These recommendations are based on the results obtained with the usage of G-CSF in a variety of solid malignancies, mostly breast cancer and lymphomas [8,15]. Experience with G-CSF in prostate cancer is very limited for at least two reasons.…”

Section: Discussionmentioning

confidence: 98%

Peg-filgrastim and cabazitaxel in prostate cancer patients

et al. 2013

View full text Add to dashboard Cite

To determine the impact of prophylaxis with granulocyte-colony stimulating growth factor (G-CSF) on the risk of febrile neutropenia in a cohort of patients enrolled at the University Federico II of Naples and treated with cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC). We carried out a retrospective review of prospectively collected data of patients enrolled at our institution in a compassionate-use programme with cabazitaxel, aimed at providing early access to the drug before its commercial availability in mCRPC patients. Besides baseline clinical and demographic characteristics, data on treatment efficacy and toxicity, as well as those on the use of G-CSF per patient per cycle were extracted. Progression-free survival and overall survival were calculated using the Kaplan-Meier method. Fisher's exact test was used to explore a relationship between a single event of grade 3 or more neutropenia or febrile neutropenia and previous use of G-CSF. Univariate analysis was carried out to evaluate predictors of grade 3 or more neutropenia and/or febrile neutropenia. Of 34 patients enrolled at our institution from December 2010 to December 2011, 32 had received at least one dose of cabazitaxel and were included in the analysis. Patients received a median of 10 cabazitaxel cycles. Grade 3 or more neutropenia was common, occurring in 64.5% of patients. Three patients (9.3%) developed febrile neutropenia. Twenty-seven patients received prophylaxis with G-CSF during at least one cycle using peg-filgrastim. The risk of grade 3 or more neutropenia and/or febrile neutropenia per patient and per cycle was seven times lower when G-CSF was used. Baseline neutrophil count of less than 4570/mm was the strongest predictor of grade 3 or more neutropenia and/or febrile neutropenia. No toxic death was reported. Only one patient discontinued cabazitaxel because of an adverse event. Our analysis suggests that prophylaxis with peg-filgrastim may considerably reduce the incidence of grade 3 or more neutropenia and, possibly, of febrile neutropenia in mCRPC patients treated with cabazitaxel. Further analyses involving a larger population are warranted to confirm our results.

show abstract

Section: Discussionmentioning

confidence: 98%

Peg-filgrastim and cabazitaxel in prostate cancer patients

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The EORTC guidelines complement previously published guidelines on the use of these agents in the elderly [37]. In 2005, the NCCN published myeloid growth factor guidelines, which have been updated annually through 2007 [34,35]. ASCO published their original colony-stimulating factor guidelines in 1994 with updates in 1996, 1997 and 2000, only recently completing the most recent update in 2006 representing the most extensive revision of these guidelines to date [38,39].…”

Section: Clinical Practice Guidelines For the Myeloid Growth Factorsmentioning

confidence: 96%

“…Myeloid growth factor guidelines from the NCCN were initially put forward in 2005 and have been updated annually [34,35]. These guidelines recommend a process starting with an initial evaluation based on the type of cancer, chemotherapy regimen, patient-specific risk factors and treatment intention (Fig.…”

Section: Guidelines Of the National Comprehensive Cancer Networkmentioning

confidence: 99%

Granulocyte colony-stimulating factors: finding the right indication

Lyman

Shayne²

2007

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…2,3,17 Without appropriate management, neutropenia and FN can lead to reduced or delayed chemotherapy doses, which may compromise disease control and survival. 17,97,98 Studies of patients with breast cancer showed that neutropenia-related complications resulted in dose delay or dose reductions in 28-58% of patients. 17,99 These delays and reductions were more common in patients aged ≥65 years, with 67% of elderly patients receiving a median dose intensity < 85% of the planned dose.…”

Section: Challenge Of Neutropenia and Febrile Neutropenia In Elderly mentioning

confidence: 99%